Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Marinus Pharma CS (MRNS)

Marinus Pharma CS (MRNS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 197,585
  • Shares Outstanding, K 37,140
  • Annual Sales, $ 15,350 K
  • Annual Income, $ -98,780 K
  • 60-Month Beta 1.49
  • Price/Sales 12.97
  • Price/Cash Flow N/A
  • Price/Book 5.50
Trade MRNS with:

Options Overview Details

View History
  • Implied Volatility 79.06% ( -30.26%)
  • Historical Volatility 97.13%
  • IV Percentile 64%
  • IV Rank 10.69%
  • IV High 352.50% on 05/13/22
  • IV Low 46.32% on 06/07/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 57
  • Put/Call OI Ratio 0.89
  • Today's Open Interest 5,078
  • Open Int (30-Day) 4,165

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.53
  • Number of Estimates 6
  • High Estimate 1.47
  • Low Estimate -1.03
  • Prior Year -0.65
  • Growth Rate Est. (year over year) +18.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.19 +26.97%
on 05/12/22
7.87 -32.40%
on 04/25/22
-2.06 (-27.91%)
since 04/20/22
3-Month
4.19 +26.97%
on 05/12/22
12.37 -56.99%
on 03/18/22
-5.88 (-52.50%)
since 02/18/22
52-Week
4.19 +26.97%
on 05/12/22
19.83 -73.17%
on 06/25/21
-10.02 (-65.32%)
since 05/20/21

Most Recent Stories

More News
Marinus Pharmaceuticals to Present at Upcoming Medical and Investor Conferences

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will participate...

MRNS : 5.32 (-0.75%)
Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Tops Revenue Estimates

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 40.23% and 548.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?...

MRNS : 5.32 (-0.75%)
LJPC : 3.94 (-2.96%)
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial...

MRNS : 5.32 (-0.75%)
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards...

MRNS : 5.32 (-0.75%)
Corcept Therapeutics (CORT) Misses Q1 Earnings and Revenue Estimates

Corcept (CORT) delivered earnings and revenue surprises of -13.04% and 5.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

CORT : 20.42 (+0.84%)
MRNS : 5.32 (-0.75%)
Analysts Estimate Marinus Pharmaceuticals (MRNS) to Report a Decline in Earnings: What to Look Out for

Marinus Pharmaceuticals (MRNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MRNS : 5.32 (-0.75%)
Marinus Pharmaceuticals Announces Resumption of Phase 3 RAISE Trial in Status Epilepticus

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has resumed screening...

MRNS : 5.32 (-0.75%)
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2022 Financial Results on May 12, 2022

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial...

MRNS : 5.32 (-0.75%)
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of an inducement award...

MRNS : 5.32 (-0.75%)
Marinus Pharmaceuticals Announces Publication in The Lancet Neurology of ZTALMY® (ganaxolone) Phase 3 Marigold Trial Results

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that The Lancet Neurology has...

MRNS : 5.32 (-0.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment of epilepsy and other targeted neurological, behavioral and psychiatric disorders. The Company offers Ganaxolone which has completed Phase II clinical...

See More

Key Turning Points

3rd Resistance Point 6.34
2nd Resistance Point 6.06
1st Resistance Point 5.69
Last Price 5.32
1st Support Level 5.05
2nd Support Level 4.77
3rd Support Level 4.40

See More

52-Week High 19.83
Fibonacci 61.8% 13.86
Fibonacci 50% 12.01
Fibonacci 38.2% 10.16
Last Price 5.32
52-Week Low 4.19

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar